Sanara MedTech Inc.
SMTISanara MedTech Inc. in brief
Sanara MedTech Inc. is a listed company in the Medical Care Facilities industry, based in Fort Worth, Texas, USA. Its market value was $304 M on 20 October 2026, which makes it the 14,719th largest listed company in the world and the 2,864th largest in the USA on this site. In the year to December 2025 it had sales of $103 M and a net loss of $38 M. Seth D. Yon is its chief executive. Its largest product and service lines by sales in 2025 were Soft Tissue Repair Products (89%) and Bone Fusion Products (11%). Its shares trade under the symbol SMTI (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Sanara MedTech Inc.
We are a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market. Our products are designed to achieve our goal of providing better clinical outcomes at a lower overall cost for healthcare systems. We strive to be one of the most innovative and comprehensive providers of effective surgical solutions and are continually seeking to expand our offerings for patients requiring surgical treatments in the United States.
We primarily market and sell soft tissue repair and bone fusion products for use in the operating room or other sterile environments. Our soft tissue repair products include, among other products, our lead product, CellerateRX Surgical Powder, a hydrolyzed collagen that aids in the management of surgical wounds, and BIASURGE Advanced Surgical Solution, a sterile no-rinse, advanced surgical solution used for wound irrigation. Our bone fusion products include, among other products, BiFORM Bioactive Moldable Matrix, an osteoconductive, bioactive, porous implant that allows for bony ingrowth across the graft site, and ALLOCYTE Plus Advanced Viable Bone Matrix, a human allograft cellular bone matrix containing bone-derived progenitor cells and conformable bone fibers.
From the company's annual report filed with the US SEC: read the report
Sanara MedTech Inc. timeline
- 1996
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- ✎Renamed Mb Software CorpFormerly Inav Travel Corporation.
- 2008
- ✎Renamed Wound Management Technologies, Inc.Formerly Mb Software Corp.
- 2019
- ✎Renamed Sanara MedTech Inc.Formerly Wound Management Technologies, Inc..
- 2025
- 💰Record revenue of $103 millionFY2025, the highest of the 8 years on record.
- 💰Record net income of $38 millionFY2025, the highest profit of the 3 years on record.
Events of Sanara MedTech Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #4,076 (Jan 2020) · #2,915 (Jan 2021) · #3,783 (Jan 2022) · #3,003 (Dec 2022) · #3,063 (Jul 2023) · #2,825 (Jan 2024) · #1,771 (Mar 2026) · #2,835 (Aug 2026) · #2,824 (Oct 2026) · #2,868 (Oct 2026)
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- 2.7×
- Price / book
- 51.2×
- Free cash flow yield
- 0.7%
- Net margin (TTM)
- -2.7%
- Operating margin
- 7.1%
- Return on equity
- -50.7%
- Liabilities / assets
- 91.9%
- Net debt
- $29M
- Revenue growth
- +19.0%
- R&D / revenue
- 4.9%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $103M | +19.0% | $7M | $-38M | -36.4% |
| Dec 2024 | $87M | +33.4% | $1M | $-10M | -11.1% |
| Dec 2023 | $65M | +41.8% | $-4M | $-4M | -6.6% |
| Dec 2022 | $46M | +89.9% | $-13M | $-8M | -17.3% |
| Dec 2021 | $24M | +54.8% | $-7M | $-8M | -32.8% |
| Dec 2020 | $16M | +32.5% | $-5M | $-4M | -28.5% |
| Dec 2019 | $12M | +101.5% | $-3M | $-3M | -23.9% |
| Dec 2018 | $6M | — | $-1M | $-1M | -10.3% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $7M | $5M | $2M | $-4.36 | — |
| Dec 2024 | $-0M | $0M | $-0M | $-1.14 | — |
| Dec 2023 | $-3M | $0M | $-4M | $-0.52 | — |
| Dec 2022 | $-6M | $0M | $-6M | $-1.00 | — |
| Dec 2021 | $-5M | $0M | $-5M | $-1.08 | — |
| Dec 2020 | $-4M | $1M | $-5M | $-0.76 | — |
| Dec 2019 | $-2M | $0M | $-2M | $-1.32 | — |
| Dec 2018 | $0M | $0M | $0M | $0.00 | — |
Quarterly results
Latest quarter to Sep 2026: revenue $28M (+8.0% on a year earlier), net income $-1M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 12, 202610-QQuarterly report · period to Sep 2026
- Nov 12, 20268-KCurrent reportResults of operations
- Oct 29, 20268-KCurrent reportRegulation FD disclosure
- Oct 16, 20268-KCurrent reportOther events
- Oct 1, 20268-KCurrent reportShareholder vote · Other events
- Aug 11, 202610-QQuarterly report · period to Jun 2026
- Aug 11, 20268-KCurrent reportResults of operations
- Aug 11, 20268-K/ACurrent report (amended)Material agreement · Regulation FD disclosure
- Jul 29, 20268-KCurrent reportMaterial agreement · Regulation FD disclosure
- Jun 9, 20268-KCurrent reportShareholder vote
- Jun 4, 20268-KCurrent reportAgreement ended
- May 12, 202610-QQuarterly report · period to Mar 2026
Official filings of Sanara MedTech Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $103 M
- Operating income
- $7 M
- Net income
- $-38 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $73 M
- Total liabilities
- $67 M
- Total equity
- $6 M
As of December-2025
Top 84 institutional investors in Sanara MedTech Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 429,517 | +180,690 (+72.62%) | 4.68% | $15 M | Nov 13, 2026 |
| 2 | Glazer Capital, LLC | 349,684 | New | 3.81% | $12 M | Nov 17, 2026 |
| 3 | Vanguard Capital Management LLC | 194,897 | 0 (0.00%) | 2.12% | $7 M | Nov 13, 2026 |
| 4 | Qube Research & Technologies Ltd | 176,318 | +155,918 (+764.30%) | 1.92% | $6 M | Nov 13, 2026 |
| 5 | Transmarket Holdings LP | 148,956 | New | 1.62% | $5 M | Oct 27, 2026 |
| 6 | Abc Arbitrage SA | 140,894 | New | 1.53% | $5 M | Oct 23, 2026 |
| 7 | Toronto Dominion Bank | 119,900 | New | 1.31% | $4 M | Nov 16, 2026 |
| 8 | Renaissance Technologies LLC | 114,100 | +46,700 (+69.29%) | 1.24% | $4 M | Nov 12, 2026 |
| 9 | Gardner Lewis Asset Management L P | 112,461 | New | 1.22% | $4 M | Nov 13, 2026 |
| 10 | Geode Capital Management, LLC | 105,346 | +16,167 (+18.13%) | 1.15% | $4 M | Nov 6, 2026 |
| 11 | Alberta Investment Management Corp | 102,400 | New | 1.12% | $4 M | Nov 9, 2026 |
| 12 | Polar Asset Management Partners Inc. | 82,182 | New | 0.90% | $3 M | Nov 16, 2026 |
| 13 | State Street Corp | 68,241 | +4,772 (+7.52%) | 0.74% | $2 M | Nov 12, 2026 |
| 14 | Sagefield Capital LP | 65,782 | New | 0.72% | $2 M | Nov 16, 2026 |
| 15 | ExodusPoint Capital Management, LP | 53,605 | New | 0.58% | $2 M | Nov 16, 2026 |
| 16 | Morgan Stanley | 46,044 | +22,416 (+94.87%) | 0.50% | $2 M | Nov 13, 2026 |
| 17 | D. E. Shaw & Co., Inc. | 45,741 | +29,371 (+179.42%) | 0.50% | $2 M | Nov 16, 2026 |
| 18 | Northern Trust Corp | 44,266 | +7,825 (+21.47%) | 0.48% | $2 M | Nov 16, 2026 |
| 19 | Millennium Management LLC | 36,990 | New | 0.40% | $1 M | Nov 16, 2026 |
| 20 | Royal Bank Of Canada | 35,143 | -95,852 (-73.17%) | 0.38% | $1 M | Nov 16, 2026 |
| 21 | Vanguard Portfolio Management LLC | 33,852 | +10,435 (+44.56%) | 0.37% | $1 M | Nov 13, 2026 |
| 22 | FMR LLC | 29,616 | +28,489 (+2527.86%) | 0.32% | $1 M | Nov 10, 2026 |
| 23 | Goldman Sachs Group Inc | 28,998 | -45,200 (-60.92%) | 0.32% | $1 M | Nov 16, 2026 |
| 24 | Vanguard Fiduciary Trust Co | 28,899 | +2,872 (+11.03%) | 0.31% | $1 M | Nov 13, 2026 |
| 25 | Natixis | 28,839 | New | 0.31% | $1 M | Nov 6, 2026 |
Show all 84: investors 26 to 84
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Russell Investments Group, Ltd. | 26,285 | +25,309 (+2593.14%) | 0.29% | $1 M | Nov 6, 2026 |
| 27 | Jane Street Group, LLC | 26,222 | -24,584 (-48.39%) | 0.29% | $1 M | Nov 12, 2026 |
| 28 | Credit Industriel Et Commercial | 26,183 | New | 0.29% | $1 M | Nov 13, 2026 |
| 29 | AQR Capital Management LLC | 25,965 | -86,242 (-76.86%) | 0.28% | $1 M | Nov 16, 2026 |
| 30 | Hill Island Financial LLC | 24,291 | New | 0.26% | $1 M | Oct 20, 2026 |
| 31 | Price T Rowe Associates Inc /MD/ | 20,214 | +962 (+5.00%) | 0.22% | $1 M | Nov 16, 2026 |
| 32 | Rockefeller Capital Management L.P. | 18,742 | +4,349 (+30.22%) | 0.20% | $1 M | Nov 13, 2026 |
| 33 | Jump Financial, LLC | 17,000 | New | 0.19% | $1 M | Nov 13, 2026 |
| 34 | Bank of New York Mellon Corp | 16,061 | New | 0.17% | $1 M | Nov 5, 2026 |
| 35 | Dimensional Fund Advisors LP | 15,748 | +6,372 (+67.96%) | 0.17% | $1 M | Nov 4, 2026 |
| 36 | Water Island Capital LLC | 14,601 | New | 0.16% | $1 M | Nov 13, 2026 |
| 37 | Charles Schwab Investment Management Inc | 13,473 | +3,463 (+34.60%) | 0.15% | $0 M | Nov 16, 2026 |
| 38 | Carlson Capital, L.P. | 13,300 | New | 0.14% | $0 M | Nov 9, 2026 |
| 39 | Nuveen, LLC | 11,529 | +428 (+3.86%) | 0.13% | $0 M | Nov 10, 2026 |
| 40 | Janney Montgomery Scott LLC | 10,030 | -7,500 (-42.78%) | 0.11% | $0 M | Nov 12, 2026 |
| 41 | Two Sigma Investments, LP | 9,678 | New | 0.11% | $0 M | Nov 16, 2026 |
| 42 | Citigroup Inc | 8,687 | +4,671 (+116.31%) | 0.09% | $0 M | Nov 4, 2026 |
| 43 | Mint Tower Capital Management B.V. | 8,462 | New | 0.09% | $0 M | Nov 9, 2026 |
| 44 | American Century Companies Inc | 7,411 | New | 0.08% | $0 M | Nov 12, 2026 |
| 45 | State Board Of Administration Of Florida Retirement System | 7,100 | New | 0.08% | $0 M | Nov 13, 2026 |
| 46 | Bank Of America Corp /de/ | 6,336 | -9,609 (-60.26%) | 0.07% | $0 M | Nov 16, 2026 |
| 47 | Wealthspire Advisors, LLC | 6,109 | New | 0.07% | $0 M | Nov 13, 2026 |
| 48 | Canada Pension Plan Investment Board | 5,800 | New | 0.06% | $0 M | Nov 16, 2026 |
| 49 | Rhumbline Advisers | 4,651 | +2,101 (+82.39%) | 0.05% | $0 M | Nov 10, 2026 |
| 50 | UBS Group AG | 4,635 | +4,279 (+1201.97%) | 0.05% | $0 M | Nov 10, 2026 |
| 51 | Deutsche Bank AG\ | 3,591 | -552 (-13.32%) | 0.04% | $0 M | Nov 6, 2026 |
| 52 | MetLife Investment Management, LLC | 3,040 | New | 0.03% | $0 M | Nov 16, 2026 |
| 53 | New York State Common Retirement Fund | 2,433 | 0 (0.00%) | 0.03% | $0 M | Nov 17, 2026 |
| 54 | Jpmorgan Chase & Co | 2,401 | -229 (-8.71%) | 0.03% | $0 M | Nov 12, 2026 |
| 55 | MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | 2,334 | +781 (+50.29%) | 0.03% | $0 M | Nov 16, 2026 |
| 56 | Barclays PLC | 2,116 | -157 (-6.91%) | 0.02% | $0 M | Nov 6, 2026 |
| 57 | Vanguard Global Advisers, LLC | 1,786 | +881 (+97.35%) | 0.02% | $0 M | Nov 13, 2026 |
| 58 | Wells Fargo & Company/mn | 1,482 | -1,597 (-51.87%) | 0.02% | $0 M | Nov 16, 2026 |
| 59 | Police & Firemen's Retirement System of New Jersey | 1,359 | +576 (+73.56%) | 0.01% | $0 M | Nov 9, 2026 |
| 60 | BNP Paribas Financial Markets | 1,335 | -12,904 (-90.62%) | 0.01% | $0 M | Nov 12, 2026 |
| 61 | Arax Advisory Partners | 635 | -672 (-51.42%) | 0.01% | $0 M | Nov 12, 2026 |
| 62 | Legal & General Group Plc | 426 | +143 (+50.53%) | 0.00% | $0 M | Nov 16, 2026 |
| 63 | Tower Research Capital LLC (TRC) | 386 | -449 (-53.77%) | 0.00% | $0 M | Nov 16, 2026 |
| 64 | Ameritas Investment Partners, Inc. | 313 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 65 | UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 222 | New | 0.00% | $0 M | Nov 16, 2026 |
| 66 | Osaic Holdings, Inc. | 188 | 0 (0.00%) | 0.00% | $0 M | Nov 12, 2026 |
| 67 | Sterling Capital Management LLC | 161 | +149 (+1241.67%) | 0.00% | $0 M | Oct 22, 2026 |
| 68 | GAMMA Investing LLC | 80 | 0 (0.00%) | 0.00% | $0 M | Oct 8, 2026 |
| 69 | Mather Group, LLC. | 69 | New | 0.00% | $0 M | Oct 14, 2026 |
| 70 | SJS Investment Consulting Inc. | 65 | +58 (+828.57%) | 0.00% | $0 M | Oct 26, 2026 |
| 71 | Spire Wealth Management | 60 | 0 (0.00%) | 0.00% | $0 M | Oct 30, 2026 |
| 72 | IFP Advisors, Inc | 51 | -31 (-37.80%) | 0.00% | $0 M | Oct 16, 2026 |
| 73 | Allworth Financial LP | 48 | -108 (-69.23%) | 0.00% | $0 M | Nov 17, 2026 |
| 74 | Parkside Financial Bank & Trust | 45 | New | 0.00% | $0 M | Oct 27, 2026 |
| 75 | California State Teachers Retirement System | 43 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 76 | Essential Partners LLC | 39 | -75 (-65.79%) | 0.00% | $0 M | Oct 14, 2026 |
| 77 | Global Retirement Partners, LLC | 38 | New | 0.00% | $0 M | Nov 10, 2026 |
| 78 | Root Financial Partners, LLC | 38 | New | 0.00% | $0 M | Oct 21, 2026 |
| 79 | True Wealth Design, LLC | 35 | -32 (-47.76%) | 0.00% | $0 M | Oct 13, 2026 |
| 80 | EverSource Wealth Advisors, LLC | 30 | -124 (-80.52%) | 0.00% | $0 M | Nov 4, 2026 |
| 81 | Caitong International Asset Management Co., Ltd | 23 | New | 0.00% | $0 M | Oct 29, 2026 |
| 82 | PNC Financial Services Group, Inc. | 18 | New | 0.00% | $0 M | Nov 6, 2026 |
| 83 | Farther Finance Advisors, LLC | 18 | -32 (-64.00%) | 0.00% | $0 M | Oct 8, 2026 |
| 84 | Rothschild Investment LLC | 9 | -26 (-74.29%) | 0.00% | $0 M | Nov 10, 2026 |
Mutual funds holding Sanara MedTech Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 148,899 | $4 M | 1.6% | <0.01% | +41% | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors | 74,682 | $2 M | 0.81% | <0.01% | −4.4% | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC | 36,350 | $1 M | 0.40% | <0.01% | +21% | Jul 31, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 42,865 | $1 M | 0.47% | <0.01% | −0.3% | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors | 31,668 | $1 M | 0.34% | <0.01% | +30% | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 19,525 | $0 M | 0.21% | <0.01% | +1.0% | May 31, 2026 |
| 🇺🇸 U.S. Small Cap Equity FundRussell Investment Management, LLC | 11,038 | $0 M | 0.12% | 0.04% | new | Jul 31, 2026 |
| 🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc. | 15,524 | $0 M | 0.17% | <0.01% | +2.9% | May 31, 2026 |
| 🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc. | 8,345 | $0 M | 0.09% | <0.01% | +44% | Jul 31, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 11,230 | $0 M | 0.12% | 0.02% | +43% | Jun 30, 2026 |
| 🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P. | 9,609 | $0 M | 0.10% | <0.01% | +60% | Jun 30, 2026 |
| 🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC | 5,089 | $0 M | 0.06% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 6,529 | $0 M | 0.07% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 5,716 | $0 M | 0.06% | <0.01% | +11% | May 31, 2026 |
| 🇺🇸 U.S. Micro Cap PortfolioDimensional Fund Advisors LP | 3,812 | $0 M | 0.04% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC | 5,191 | $0 M | 0.06% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 5,177 | $0 M | 0.06% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC | 3,962 | $0 M | 0.04% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Dimensional U.S. Small Cap ETFDimensional Fund Advisors LP | 2,700 | $0 M | 0.03% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC | 3,200 | $0 M | 0.03% | <0.01% | +40% | Jun 30, 2026 |
| 🇺🇸 Vanguard Russell 2000 Growth Index FundThe Vanguard Group, Inc. | 2,941 | $0 M | 0.03% | <0.01% | +2.9% | May 31, 2026 |
| 🇺🇸 Strategic Advisers U.S. Total Stock FundStrategic Advisers LLC | 2,800 | $0 M | 0.03% | <0.01% | +7.5% | May 31, 2026 |
| 🇺🇸 Small Cap Core FundNorthern Trust Investments, Inc. | 2,404 | $0 M | 0.03% | 0.01% | −4.6% | Jun 30, 2026 |
| 🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc. | 1,654 | $0 M | 0.02% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Venerable US Small Cap FundVenerable Investment Advisers, LLC | 2,346 | $0 M | 0.03% | 0.03% | −2.9% | Jun 30, 2026 |
| 🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC | 1,600 | $0 M | 0.02% | <0.01% | +16% | Jul 31, 2026 |
| 🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC | 2,210 | $0 M | 0.02% | <0.01% | +46% | Jun 30, 2026 |
| 🇺🇸 Goldman Sachs ActiveBeta U.S. Small Cap Equity ETFGoldman Sachs Asset Management, L.P. | 2,135 | $0 M | 0.02% | <0.01% | +1.3% | May 31, 2026 |
| 🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation | 1,900 | $0 M | 0.02% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 1,854 | $0 M | 0.02% | <0.01% | −39% | Jun 30, 2026 |
| 🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc. | 1,830 | $0 M | 0.02% | <0.01% | −11% | Jun 30, 2026 |
| 🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 1,630 | $0 M | 0.02% | <0.01% | +75% | Jun 30, 2026 |
| 🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC | 1,600 | $0 M | 0.02% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 1,279 | $0 M | 0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company | 1,121 | $0 M | 0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc. | 1,000 | $0 M | 0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC | 615 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC | 878 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 U.S. Small Cap PortfolioDimensional Fund Advisors LP | 605 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 U.S. Small Cap Growth PortfolioDimensional Fund Advisors LP | 586 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc. | 565 | $0 M | <0.01% | <0.01% | +60% | Jul 31, 2026 |
| 🇺🇸 JNL/DFA U.S. Small Cap FundJackson National Asset Management, LLC | 767 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 747 | $0 M | <0.01% | <0.01% | +18% | Jun 30, 2026 |
| 🇺🇸 Dimensional U.S. Core Equity 2 ETFDimensional Fund Advisors LP | 509 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Dimensional US Sustainability Core 1 ETFDimensional Fund Advisors LP | 439 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Bridge Builder Small/Mid Cap Growth FundOLIVE STREET INVESTMENT ADVISERS LLC | 628 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Avantis U.S. Small Cap Equity ETFAmerican Century ETF Trust | 572 | $0 M | <0.01% | <0.01% | new | May 31, 2026 |
| 🇺🇸 College Retirement Equities Fund - Total Global Stock AccountTIAA-CREF Investment Management, LLC | 549 | $0 M | <0.01% | <0.01% | −94% | Jun 30, 2026 |
| 🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC | 345 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS | 487 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 TIAA Separate Account VA-1 - Stock Index AccountTeachers Advisors, LLC | 448 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc. | 435 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC | 433 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 SmallCap Growth Fund IPrincipal Global Investors, LLC | 291 | $0 M | <0.01% | <0.01% | −6.1% | Jul 31, 2026 |
| 🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc. | 378 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 EQ/Morgan Stanley Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 353 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management | 313 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Russell 3000 Index FundThe Vanguard Group, Inc. | 294 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC | 252 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS | 160 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 PD Small-Cap Growth Index PortfolioPacific Life Fund Advisors LLC | 214 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC | 167 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 ProShares Russell 2000 High Income ETFPROSHARE ADVISORS LLC | 143 | $0 M | <0.01% | <0.01% | +7.5% | May 31, 2026 |
| 🇺🇸 Morgan Stanley Pathway Small-Mid Cap Equity ETFCONSULTING GROUP ADVISORY SERVICES LLC | 129 | $0 M | <0.01% | <0.01% | −9.8% | May 31, 2026 |
| 🇺🇸 ProShares Ultra Russell2000PROSHARE ADVISORS LLC | 112 | $0 M | <0.01% | <0.01% | −40% | May 31, 2026 |
| 🇺🇸 ProShares UltraPro Russell2000PROSHARE ADVISORS LLC | 114 | $0 M | <0.01% | <0.01% | −39% | May 31, 2026 |
| 🇺🇸 Destinations Small-Mid Cap Equity FundBrinker Capital Investments, LLC | 91 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Knights of Columbus U.S. ALL CAP INDEX FUNDKnights of Columbus Asset Advisors LLC | 27 | $0 M | <0.01% | <0.01% | +35% | Jul 31, 2026 |
| 🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc. | 34 | $0 M | <0.01% | <0.01% | −71% | Jun 30, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 69 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Sanara MedTech Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Seth D. YonChief Executive Officer, Director | Shares withheld for tax | -3,661 | $35.11 | $129 K | 105,885 | Form 4 |
| filed | Sara N. OrtweinDirector | Grant or award | +4,616 | — | — | 25,415 | Form 4 |
| filed | Eric D. TanzbergerDirector | Grant or award | +5,308 | — | — | 22,966 | Form 4 |
| filed | Ronald T. NixonDirector, 10% owner | Grant or award | +4,154 | — | — | 68,196 | Form 4 |
| filed | Roszell Mack IIIDirector | Grant or award | +5,308 | — | — | 21,842 | Form 4 |
| filed | Eric D. MajorDirector | Grant or award | +4,846 | — | — | 14,232 | Form 4 |
| filed | Robert Andrew DeSutterDirector | Grant or award | +5,539 | — | — | 28,740 | Form 4 |
| filed | Keith G. MyersDirector | Grant or award | +4,385 | — | — | 9,325 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Sanara MedTech Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Trading halts
- 2026-07-29 18:21 UTC, code T3, resumed 20:30 UTC
Fails to deliver
- : 16,834 shares at $33.14
- : 10 shares at $35.09
- : 10 shares at $35.00
- : 5 shares at $35.14
- : 668 shares at $35.10
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Sanara MedTech Inc. scorecard#
Passes 9 of the 23 checks that could be worked out: strongest in growth (4 of 6), weakest in valuation (0 of 5). Fiscal year 2025; market cap of Oct 20, 2026.
Valuation0 of 5
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✗Price to book below its peers' median51.2×Price to book 51.2× against Medical Care Facilities's median of 4.0×.
- ✗Price to sales below its peers' median2.7×Price to sales 2.7× against Medical Care Facilities's median of 1.4×.
- ✗Free cash flow yield above 5%0.7%Free cash flow is 0.7% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth4 of 6
- ✓Revenue grew in the newest year19.0%Revenue up 19.0% in fiscal 2025.
- ✓Revenue up more than 5% a year over three years31.0%31.0% a year over the three years to fiscal 2025.
- ✓Faster growth over three years than its peers' median31.0%31.0% a year against Medical Care Facilities's median of 9.0% (33 companies).
- ✗Earnings per share grew in the newest year-4.36 vs -1.14Diluted EPS -4.36 in fiscal 2025 against -1.14 the year before (report's currency).
- ✗Net income higher than five years earlier-$38 M-$38 M in fiscal 2025 against -$4 M in 2020.
- ✓Revenue rose in at least four of the last five years5 of 5Revenue rose in 5 of the five years to fiscal 2025.
Profitability1 of 5
- ✗Profitable in the newest year-$38 MNet income -$38 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- ✗Operating margin above its peers' median7.1%7.1% against Medical Care Facilities's median of 7.9% (36 companies).
- ✗Return on equity above 15%-165.7%-165.7% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- ✓Operating margin wider than three years earlier7.1%7.1% in fiscal 2025 against -27.3% in 2022.
Financial health3 of 6
- ✓Short-term assets cover short-term liabilities1.8×Current ratio 1.80 at the end of fiscal 2025.
- ✗Debt below equity7.7×Debt to equity 7.74 at the end of fiscal 2025.
- ✓Net debt below three years of EBITDA2.6×Net debt 2.6 times EBITDA in fiscal 2025.
- ✗Operating income covers interest five times1.1×Operating income 1.1 times interest in fiscal 2025.
- ✗Cash from operations positive in each of the last three years1 of 3Positive in 1 of the three years to fiscal 2025.
- ✓Altman Z-score outside the distress zone3.27Z-score 3.27 (safe zone) for fiscal 2025.
Shareholder returns1 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✓Share count up no more than 2% in a year1.6%Diluted shares up 1.6% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Medical Care Facilities, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from Sanara MedTech Inc.'s statements, beside the median of Medical Care Facilities.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | 7.1% | 7.9% | |
| Net margin | -36.4% | 3.2% | |
| Return on equity | -165.7% | 8.2% | |
| Revenue growth, 3 years a year | 31.0% | 9.0% | |
| Revenue growth | 19.0% | 6.7% | |
| Debt to equity | 7.74× | 0.56× |
4of 9on the Piotroski tests of financial strength
- Net loss of $38 million, the 8th loss-making year in a row.
- Operating income covers the interest bill only 1.1 times.
- Goodwill and intangibles ($22 million) exceed shareholders' equity ($6 million).
- Revenue has grown 7 years in a row.
Sanara MedTech Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 103+19.0%100% | 87+33.4%100% | 65+41.8%100% | 46+89.9%100% | 24+54.9%100% | 16+32.5%100% | 12+102%100% | 5.8−7.4%100% | 6.3+14.5%100% | 5.5—100% | |
| Cost of revenue | 7.5−7.6%7.3% | 8.1+3.7%9.4% | 7.9+23.5%12.1% | 6.4+175%13.9% | 2.3+43.0%9.6% | 1.6+33.7%10.4% | 1.2+138%10.3% | 0.5−37.0%8.7% | 0.8−14.6%12.8% | 0.9—17.1% | |
| Gross profit | 96+21.7%92.7% | 79+37.4%90.6% | 57+44.7%87.9% | 39+80.8%86.1% | 22+56.3%90.4% | 14+32.3%89.6% | 11+98.1%89.7% | 5.3−3.1%91.3% | 5.5+20.5%87.2% | 4.6—82.9% | |
| Research and development | 5.1+79.3%4.9% | 2.8r5.7−31.5%3.3% | 4.1+22.7%6.4% | 3.4+503%7.3% | 0.6+1290%2.3% | 0.0—0.3% | — | — | — | — | |
| Selling, general and administrative | 79+9.8%76.3% | 72r77+25.8%82.7% | 57+24.0%87.7% | 46+63.9%100% | 28—116% | — | — | — | — | — | |
| Selling and marketing | 62+10.2%60.1% | 56—64.9% | — | — | — | — | — | — | — | — | |
| General and administrative | 17+8.6%16.2% | 15—17.8% | — | — | 28+50.2%116% | 19r19+42.9%120% | 13+128%111% | 5.7+8.7%98.3% | 5.3+33.7%83.7% | 3.9—71.6% | |
| Operating expenses | 88+14.3%85.6% | 77r85+26.0%89.2% | 61+18.0%94.4% | 52r52+78.0%113% | 29+53.7%121% | 19+42.9%122% | 13+128%113% | 5.8+8.4%99.9% | 5.4+11.2%85.3% | 4.8—87.8% | |
| Operating income | 7.3+480%7.1% | 1.3r−6.7—1.5% | −4.2—−6.5% | −13r−12—−27.3% | −7.4—−30.6% | −5.0—−32.3% | −2.7—−23.3% | −0.5−517%−8.6% | 0.1—1.9% | −0.3—−4.9% | |
| Interest and finance income | — | — | — | — | — | — | — | −0.0−17762%−0.4% | 0.0+495%0.0% | 0.0—0.0% | |
| Interest expense and finance costs | 6.8+116%6.6% | 3.1+558%3.6% | 0.5+67.1%0.7% | 0.3+39949%0.6% | 0.0−93.8%0.0% | 0.0−89.1%0.1% | 0.1+22.3%0.9% | 0.1−31.7%1.5% | 0.1−27.3%2.0% | 0.2—3.2% | |
| Share of profit of associates | −1.0—−0.9% | −0.1—−0.1% | — | −0.4—−0.8% | −0.6—−2.6% | — | — | −0.0—−0.2% | 0—0.0% | — | |
| Other non-operating income (expense) | −7.7—−7.5% | −3.2—−3.7% | −0.2—−0.3% | −1.4r−1.7—−3.1% | −0.6−205%−2.6% | 0.6—3.8% | −0.1—−0.8% | −0.1−147%−1.7% | 0.2—3.3% | −0.1—−2.6% | |
| Income before tax | −0.4—−0.4% | −1.9—−2.2% | −4.4—−6.8% | −14—−30.4% | −8.0—−33.1% | — | — | — | — | — | |
| Income tax | — | 0.0r−0.0—0.1% | — | −5.8—−12.7% | — | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | |
| Income from continuing operations | −0.4—−0.4% | −1.9—−2.2% | — | — | — | −4.4—−28.5% | −2.8—−24.1% | — | — | — | |
| Income from discontinued operations | −37—−36.1% | −8.0—−9.2% | — | — | — | — | — | — | — | — | |
| Net income including minority interests | −38—−36.4% | −9.9—−11.4% | −4.4—−6.8% | −8.1—−17.7% | −8.0—−33.1% | — | — | — | — | — | |
| Minority interests' share of net income | −0.0—−0.0% | −0.2—−0.3% | −0.1—−0.2% | −0.2—−0.3% | −0.1—−0.3% | −0.1—−0.6% | −0.0—−0.2% | — | — | — | |
| Net income attributable to shareholders | −38—−36.4% | −9.7—−11.2% | −4.3—−6.6% | −7.9—−17.3% | −7.9r−8.0—−32.8% | −4.4r−4.4—−28.5% | −2.8—−23.9% | −0.6−281%−10.3% | 0.3—5.3% | −0.4—−7.5% | |
| Earnings per share, basic | -4.36—— | -1.14—— | -0.52—— | -1.00—— | -1.08—— | -0.76—— | -1.32—— | 0.00—— | 0.00—— | -0.01—— | |
| Earnings per share, diluted | -4.36—— | -1.14—— | -0.52—— | -1.00—— | -1.08—— | -0.76—— | -1.32—— | 0.00—— | 0.00—— | -0.01—— | |
| Shares, weighted average (basic) | 8.6+1.6%— | 8.5+2.5%— | 8.3+4.7%— | 7.9+7.7%— | 7.3+28.0%— | 5.7+169%— | 2.1−99.0%— | 217+95.0%— | 111+2.6%— | 109—— | |
| Shares, weighted average (diluted) | 8.6+1.6%— | 8.5+2.5%— | 8.3+4.7%— | 7.9+7.7%— | 7.3+28.0%— | 5.7+169%— | 2.1−99.0%— | 217+4.1%— | 209+92.1%— | 109—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 17+4.4%22.7% | 16+208%18.0% | 5.1−42.5%7.0% | 9.0−52.0%14.7% | 19+3996%51.2% | 0.5−93.1%4.6% | 6.6+3648%59.5% | 0.2r0.7−61.9%10.3% | 0.5−44.4%20.9% | 0.8—38.4% | |
| Receivables | 12—16.4% | — | — | 6.8+138%11.2% | 2.9r0.1—7.9% | 0—0.0% | — | — | — | — | |
| Inventory | 3.9+43.4%5.4% | 2.8−41.6%3.1% | 4.7+32.9%6.4% | 3.5+73.3%5.8% | 2.0+78.4%5.6% | 1.1+53.8%11.7% | 0.7+60.4%6.7% | 0.5r0−34.6%27.2% | 0.7+104%32.1% | 0.3—16.0% | |
| Other current assets | 0.9−7.2%1.3% | 1.0r1.1+68.1%1.2% | 0.6−44.9%0.8% | 1.1+20.4%1.8% | 0.9+49.9%2.5% | 0.6+278%6.2% | 0.2+512%1.5% | 0.0r0.0+0.7%1.5% | 0.0+32.8%1.2% | 0.0—0.9% | |
| Current assets | 34+0.7%46.0% | 33+75.2%37.8% | 19−7.8%25.7% | 21−16.2%33.8% | 25+449%67.6% | 4.5−49.4%45.6% | 8.9+424%79.7% | 1.7r1.0−17.0%98.9% | 2.0+2.1%91.9% | 2.0—91.9% | |
| Property, plant and equipment | 0.5+5.7%0.6% | 0.4−65.6%0.5% | 1.3−11.2%1.7% | 1.4−13.1%2.3% | 1.6+140%4.5% | 0.7+231%6.9% | 0.2+992%1.8% | 0.0r0.1−70.3%1.1% | 0.1+80.9%2.9% | 0.0—1.6% | |
| Right-of-use (leased) assets | 2.1+43.4%2.8% | 1.4−27.4%1.6% | 2.0+147%2.7% | 0.8+95.4%1.3% | 0.4−11.7%1.1% | 0.5−20.1%4.8% | 0.6—5.3% | 0—0.0% | — | — | |
| Goodwill | 3.60.0%4.9% | 3.60.0%4.1% | 3.60.0%4.9% | 3.6—5.9% | — | — | — | — | — | — | |
| Other intangible assets | 19−20.6%25.6% | 23r41−47.7%26.7% | 45+42.6%60.8% | 32+566%51.6% | 4.7+52.6%13.0% | 3.1+111%31.5% | 1.5—13.2% | 0r0.1−100%0.0% | 0.1−16.4%5.3% | 0.1—6.5% | |
| Investments in associates | 14+161%18.7% | 5.2—5.9% | — | — | — | — | — | — | 0—0.0% | — | |
| Long-term investments | 15+135%20.1% | 6.2r8.3+101%7.1% | 3.10.0%4.2% | 3.1−38.5%5.1% | 5.0+356%13.8% | 1.1—11.2% | 0—0.0% | — | — | — | |
| Non-current assets | 39−28.1%54.0% | 55−0.1%62.2% | 55+35.7%74.3% | 40+243%66.2% | 12+121%32.4% | 5.3+136%54.4% | 2.3+11943%20.3% | 0.0r2.1−89.6%1.1% | 0.2+3.0%8.1% | 0.2—8.1% | |
| Total assets | 73−17.2%100% | 88+19.3%100% | 74+21.0%100% | 61+67.7%100% | 36+270%100% | 9.8−11.6%100% | 11+550%100% | 1.7r3.0−22.9%100% | 2.2+2.1%100% | 2.2—100% | |
| Accounts payable | 2.3—3.2% | — | — | 1.4+218%2.3% | 0.4+61.5%1.2% | 0.3−19.6%2.8% | 0.3+115%3.0% | 0.2r0.1−30.5%9.2% | 0.2−5.4%10.2% | 0.2—11.0% | |
| Debt due within a year | — | — | 0.6—0.8% | — | — | — | 0—0.0% | — | — | — | |
| Current liabilities | 19+21.8%25.5% | 15+11.1%17.4% | 14+7.5%18.6% | 13+113%21.0% | 6.0+70.1%16.5% | 3.5+34.1%36.0% | 2.6+135%23.7% | 1.1r0.4−46.9%65.7% | 2.1+51.7%95.4% | 1.4—64.2% | |
| Long-term debt | 46+49.8%63.0% | 31+237%34.8% | 9.1—12.3% | — | — | — | — | — | — | — | |
| Lease liabilities (non-current) | 1.9+51.1%2.6% | 1.2−28.8%1.4% | 1.7+244%2.4% | 0.5+127%0.8% | 0.2−37.6%0.6% | 0.4−26.1%3.6% | 0.5—4.3% | 0—0.0% | — | — | |
| Non-current liabilities | 48+42.8%66.3% | 34+118%38.5% | 16+138%21.0% | 6.5+2830%10.7% | 0.2−50.2%0.6% | 0.4−78.6%4.5% | 2.1—18.8% | 0r1.5—0.0% | 0−100%0.0% | 1.2—55.3% | |
| Total liabilities | 67+36.3%91.9% | 49+67.9%55.8% | 29+51.6%39.6% | 19+209%31.6% | 6.2+56.7%17.2% | 4.0−15.6%40.6% | 4.7+321%42.5% | 1.1r1.9−46.9%65.7% | 2.1−18.5%95.4% | 2.6—119% | |
| Retained earnings | −75—−103% | −38—−42.9% | −28—−38.0% | −23—−38.3% | −15—−41.9% | −7.0—−71.6% | −2.7−2035%−24.1% | 0.1r−47—8.1% | −47—−2113% | −47—−2174% | |
| Shareholders' equity | 5.9−84.9%8.1% | 39−12.1%44.7% | 45+7.2%60.7% | 42+36.5%68.5% | 31+398%84.2% | 6.2r6.2−3.8%62.6% | 6.4r6.6+989%57.5% | 0.6r1.1+472%34.3% | 0.1—4.6% | −0.4—−19.5% | |
| Minority interests | −0.0—−0.0% | −0.5—−0.6% | −0.2—−0.3% | −0.1—−0.2% | −0.5—−1.3% | −0.3—−3.2% | −0.2—−2.0% | 0—0.0% | — | — | |
| Total equity | 5.9−84.8%8.1% | 39−12.7%44.2% | 45+6.9%60.4% | 42+38.4%68.4% | 30+416%82.8% | 5.8r5.8−8.6%59.4% | 6.4+989%57.5% | 0.6—34.3% | — | — | |
| Total liabilities and equity | 73−17.2%100% | 88+19.3%100% | 74+21.0%100% | 61+67.7%100% | 36+270%100% | 9.8−11.6%100% | 11+550%100% | 1.7r3.0−22.9%100% | 2.2+2.1%100% | 2.2—100% | |
| Shares outstanding | 8.9+2.2%— | 8.8+2.6%— | 8.5+2.8%— | 8.3+8.1%— | 7.7+21.9%— | 6.3+76.3%— | 3.6—— | — | 113+3.4%— | 110—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | 3.9−19.8%3.8% | 4.9+34.0%5.7% | 3.7+55.0%5.7% | 2.4+297%5.2% | 0.6+105%2.5% | 0.3+143%1.9% | 0.1+43.0%1.0% | 0.1+4.0%1.4% | 0.1+32.5%1.3% | 0.1—1.1% | |
| Share-based compensation | 5.2+16.2%5.0% | 4.4+28.9%5.1% | 3.4+27.4%5.3% | 2.7+1.3%5.9% | 2.7+90.2%11.1% | 1.4—9.0% | 0—0.0% | — | — | — | |
| Cash from operating activities | 6.8—6.6% | −0.0—−0.0% | −3.2—−5.0% | −5.6—−12.1% | −4.8—−19.9% | −4.0—−25.9% | −2.2−882%−18.4% | 0.3—4.7% | −0.1−134%−2.2% | 0.4—7.4% | |
| Capital expenditure | −4.6—−4.5% | −0.2—−0.2% | −0.3—−0.4% | −0.1—−0.3% | −0.2—−0.7% | −0.5—−3.5% | −0.2—−1.6% | −0.0—−0.1% | −0.0—−0.7% | −0.0—−0.1% | |
| Intangible assets bought | −0.0—−0.0% | −0.0—−0.0% | — | −0.6—−1.3% | −0.6—−2.4% | −1.1—−7.1% | −1.5—−12.9% | 0—0.0% | −0.0—−0.7% | 0—0.0% | |
| Acquisitions, net of cash acquired | — | — | −9.9—−15.3% | — | — | — | — | — | — | — | |
| Cash from investing activities | −15—−14.5% | −6.6—−7.6% | −10—−15.7% | −3.5—−7.7% | −5.3—−21.9% | −2.7—−17.6% | −1.2—−10.2% | −0.0—−0.1% | −0.1—−1.4% | −0.0—−0.1% | |
| Debt issued | — | — | — | — | — | 0.6—3.7% | — | — | — | — | |
| Cash from financing activities | 8.9−48.8%8.6% | 17+80.1%20.0% | 9.6—14.8% | −0.6−102%−1.4% | 28+4447%117% | 0.6−93.6%4.0% | 9.8—83.3% | 0—0.0% | −0.1−159%−2.3% | 0.2—4.4% | |
| Change in cash | 0.7−93.5%0.7% | 11—12.4% | −3.8—−5.9% | −9.7−153%−21.1% | 18—75.4% | −6.2−196%−39.5% | 6.4—54.7% | — | — | — | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD thousands; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 111,911+9.8%100% | 28,430+8.0%100% | 28,137+9.0%100% | 27,799+18.6%100% | 27,546*+4.7%100% | 26,334+21.5%100% | 25,804r25,831+28.0%100% | 23,434+26.4%100% | 26,305*+48.7%100% | 21,672—100% | 20,159—100% | 18,537—100% | 17,690*—100% | |
| Cost of revenue | 7,884−0.1%7.0% | 2,105+12.3%7.4% | 1,981+2.3%7.0% | 1,924+4.8%6.9% | 1,875*−16.7%6.8% | 1,874−5.9%7.1% | 1,937−3.6%7.5% | 1,835−2.9%7.8% | 2,249*+25.8%8.6% | 1,992—9.2% | 2,009—10.0% | 1,890—10.2% | 1,788*—10.1% | |
| Gross profit | 104,027+10.7%93.0% | 26,325+7.6%92.6% | 26,155+9.6%93.0% | 25,875+19.8%93.1% | 25,671*+6.7%93.2% | 24,460+24.3%92.9% | 23,867r23,894+31.5%92.5% | 21,599+29.8%92.2% | 24,056*+51.3%91.4% | 19,680—90.8% | 18,150—90.0% | 16,647—89.8% | 15,902*—89.9% | |
| Research and development | 4,673+19.2%4.2% | 724−29.7%2.5% | 1,154+9.2%4.1% | 760−20.1%2.7% | 2,036*+130%7.4% | 1,030+31.4%3.9% | 1,057r1,257+7.2%4.1% | 950r1,114+0.4%4.1% | 883r2,412*+35.6%3.4% | 784r1,360—3.6% | 986—4.9% | 946—5.1% | 652*—3.7% | |
| Selling, general and administrative | 88,811+12.6%79.4% | 24,252+22.0%85.3% | 22,602+15.1%80.3% | 21,882+14.4%78.7% | 20,076*−0.7%72.9% | 19,878+14.1%75.5% | 19,634r21,553+3.6%76.1% | 19,129r21,441+18.1%81.6% | 20,220r22,417*+23.8%76.9% | 17,420r18,993—80.4% | 18,958—94.0% | 16,192—87.4% | 16,336*—92.3% | |
| Selling and marketing | 65,917—58.9% | 16,306+5.1%57.4% | 16,869+7.6%60.0% | 17,007+12.7%61.2% | 15,735*—57.1% | 15,514—58.9% | 15,678—60.8% | 15,084—64.4% | — | — | — | — | — | |
| General and administrative | 22,894—20.5% | 7,946+82.1%28.0% | 5,733+44.9%20.4% | 4,875+20.5%17.5% | 4,340*—15.8% | 4,364—16.6% | 3,957—15.3% | 4,045—17.3% | — | — | — | — | — | |
| Operating expenses | 97,813+14.4%87.4% | 25,589+18.9%90.0% | 24,375+14.0%86.6% | 23,228+11.8%83.6% | 24,621*+13.0%89.4% | 21,518+13.8%81.7% | 21,380r23,925+1.6%82.9% | 20,774r23,679+14.3%88.6% | 21,796r24,431*+35.1%82.9% | 18,901r21,604—87.2% | 21,035—104% | 18,178—98.1% | 16,128*—91.2% | |
| Operating income | 6,213−27.0%5.6% | 736−75.0%2.6% | 1,780−28.4%6.3% | 2,647+221%9.5% | 1,050*−53.5%3.8% | 2,941+278%11.2% | 2,487r−31—9.6% | 826r−2,080—3.5% | 2,260r−375*—8.6% | 779r−1,924—3.6% | −2,885—−14.3% | −1,532—−8.3% | −226*—−1.3% | |
| Interest expense and finance costs | 7,255+16.7%6.5% | 1,813−0.3%6.4% | 1,810+1.0%6.4% | 1,799+36.6%6.5% | 1,833*+42.2%6.7% | 1,818+96.0%6.9% | 1,792+178%6.9% | 1,317+393%5.6% | 1,289*+348%4.9% | 928—4.3% | 644—3.2% | 267—1.4% | 287*—1.6% | |
| Net interest income | — | — | — | — | — | — | — | — | — | — | 644—3.2% | — | — | |
| Share of profit of associates | −1,664—−1.5% | −443—−1.6% | −434—−1.5% | −463—−1.7% | −325*—−1.2% | −289—−1.1% | −195—−0.8% | −144—−0.6% | −59*—−0.2% | −31—−0.1% | — | — | — | |
| Other non-operating income (expense) | −8,621—−7.7% | −2,023—−7.1% | −2,192—−7.8% | −2,249—−8.1% | −2,158*—−7.8% | −2,107—−8.0% | −1,987—−7.7% | −1,446r−1,447—−6.2% | −1,326*—−5.0% | −959—−4.4% | −644—−3.2% | −267—−1.4% | −36*—−0.2% | |
| Income before tax | — | — | — | — | — | — | — | — | — | — | — | — | −262*—−1.5% | |
| Income from continuing operations | −2,408−246%−2.2% | −1,287−254%−4.5% | −411−182%−1.5% | 398—1.4% | −1,107*−218%−4.0% | 834—3.2% | 500—1.9% | −621—−2.6% | 935*—3.6% | −180—−0.8% | — | — | — | |
| Income from discontinued operations | −608—−0.5% | −124—−0.4% | −42—−0.1% | 61—0.2% | −503*—−1.8% | −31,247—−119% | −2,519—−9.8% | −2,907—−12.4% | −2,635*—−10.0% | −24—−0.1% | — | — | — | |
| Net income including minority interests | −3,016—−2.7% | −1,411—−5.0% | −453—−1.6% | 459—1.6% | −1,610*—−5.8% | −30,412—−115% | −2,018—−7.8% | −3,527—−15.1% | −1,701*—−6.5% | −2,883—−13.3% | −3,529—−17.5% | −1,799—−9.7% | −262*—−1.5% | |
| Minority interests' share of net income | −0.2—−0.0% | 0.4—0.0% | 0*—0.0% | −0.4—−0.0% | −0.2*—−0.0% | −1.0—−0.0% | −4.0—−0.0% | −0.2—−0.0% | −162*—−0.6% | −25—−0.1% | −25—−0.1% | −35—−0.2% | −25*—−0.1% | |
| Net income attributable to shareholders | −3,015—−2.7% | −1,412—−5.0% | −453—−1.6% | 459—1.7% | −1,610*—−5.8% | −30,411—−115% | −2,014—−7.8% | −3,527—−15.1% | −1,539*—−5.8% | −2,858—−13.2% | −3,504—−17.4% | −1,764—−9.5% | −237*—−1.3% | |
| Earnings per share, basic | — | — | -0.05—— | 0.05—— | — | -3.52—— | -0.23—— | -0.41—— | — | -0.34—— | -0.41—— | -0.21—— | — | |
| Earnings per share, diluted | — | — | -0.05—— | 0.05—— | — | -3.40—— | -0.23—— | -0.41—— | — | -0.34—— | -0.41—— | -0.21—— | — | |
| Shares, weighted average (basic) | 8.8+1.6%— | 8.8+1.6%— | 8.7+0.6%— | 8.7+1.6%— | — | 8.6+1.5%— | 8.6+1.7%— | 8.6+1.8%— | — | 8.5—— | 8.5—— | 8.4—— | — | |
| Shares, weighted average (diluted) | 8.8−1.8%— | 8.8−1.8%— | 8.7−3.0%— | 9.0+4.9%— | — | 8.9+5.0%— | 8.9r8.6+5.4%— | 8.6+1.8%— | — | 8.5—— | 8.5—— | 8.4—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 16,788—23.2% | 16,788+12.4%23.2% | 15,421−9.1%22.3% | 13,594−34.3%19.6% | 16,579+4.4%22.7% | 14,940−8.2%21.0% | 16,959+176%17.2% | 20,688+631%21.5% | 15,878+208%18.0% | 16,277—18.4% | 6,150—8.4% | 2,828—4.0% | 5,147—7.0% | |
| Receivables | 13,889—19.2% | 13,889—19.2% | 12,573—18.2% | 13,617—19.7% | 11,998—16.4% | — | — | — | — | — | — | — | — | |
| Inventory | 3,298—4.6% | 3,298−2.6%4.6% | 3,460−1.5%5.0% | 3,121−1.2%4.5% | 3,949+43.4%5.4% | 3,386+12.6%4.8% | 3,512−1.5%3.6% | 3,159−25.3%3.3% | 2,753−41.6%3.1% | 3,008—3.4% | 3,565—4.9% | 4,229—6.0% | 4,718—6.4% | |
| Other current assets | 670—0.9% | 670−6.1%0.9% | 742−38.2%1.1% | 817−25.1%1.2% | 949−7.2%1.3% | 714+66.3%1.0% | 1,200+145%1.2% | 1,091+19.7%1.1% | 1,022r1,124+68.1%1.2% | 429—0.5% | 489—0.7% | 912—1.3% | 608—0.8% | |
| Current assets | 36,405—50.4% | 36,405+16.6%50.4% | 32,201−4.4%46.6% | 31,198−15.3%45.0% | 33,542+0.7%46.0% | 31,226−2.1%43.9% | 33,669+61.8%34.1% | 36,843+114%38.2% | 33,306+75.2%37.8% | 31,908—36.0% | 20,811—28.4% | 17,187—24.2% | 19,006—25.7% | |
| Property, plant and equipment | 317—0.4% | 317−24.1%0.4% | 427−95.2%0.6% | 459−77.7%0.7% | 457+5.7%0.6% | 417−58.1%0.6% | 8,900+697%9.0% | 2,056+72.7%2.1% | 432−65.6%0.5% | 996—1.1% | 1,116—1.5% | 1,191—1.7% | 1,258—1.7% | |
| Right-of-use (leased) assets | 1,822—2.5% | 1,822−15.4%2.5% | 1,909+75.5%2.8% | 1,994+69.9%2.9% | 2,076+43.4%2.8% | 2,155+27.6%3.0% | 1,088−39.3%1.1% | 1,174−38.0%1.2% | 1,448−27.4%1.6% | 1,689—1.9% | 1,792—2.4% | 1,895—2.7% | 1,995—2.7% | |
| Goodwill | 3,602—5.0% | 3,6020.0%5.0% | 3,6020.0%5.2% | 3,6020.0%5.2% | 3,6020.0%4.9% | 3,6020.0%5.1% | 3,6020.0%3.6% | 3,6020.0%3.7% | 3,6020.0%4.1% | 3,602—4.1% | 3,602—4.9% | 3,602—5.1% | 3,602—4.9% | |
| Other intangible assets | 16,697—23.1% | 16,697−20.9%23.1% | 17,277−57.9%25.0% | 17,860−57.5%25.8% | 18,641−20.6%25.6% | 21,101−49.8%29.7% | 40,993−4.6%41.5% | 42,014−4.4%43.6% | 23,481r41,007−47.7%26.7% | 42,029—47.5% | 42,977—58.6% | 43,954—62.0% | 44,926—60.8% | |
| Investments in associates | 12,393—17.2% | 12,393+6.9%17.2% | 12,731+33.8%18.4% | 13,164+35.9%19.0% | 13,627+161%18.7% | 11,588—16.3% | 9,516—9.6% | 9,690—10.1% | 5,213—5.9% | — | — | — | — | |
| Long-term investments | 13,393—18.5% | 13,393+6.4%18.5% | 13,731+30.6%19.9% | 14,164+32.5%20.4% | 14,627+135%20.1% | 12,588+51.3%17.7% | 10,516+241%10.6% | 10,690+247%11.1% | 6,213r8,297+101%7.1% | 8,321—9.4% | 3,084—4.2% | 3,084—4.3% | 3,084—4.2% | |
| Non-current assets | 35,830—49.6% | 35,830−10.1%49.6% | 36,946−43.2%53.4% | 38,079−36.0%55.0% | 39,402−28.1%54.0% | 39,863−29.6%56.1% | 65,098+23.8%65.9% | 59,536+10.8%61.8% | 54,786−0.1%62.2% | 56,637—64.0% | 52,572—71.6% | 53,725—75.8% | 54,865—74.3% | |
| Total assets | 72,235—100% | 72,235+1.6%100% | 69,146−30.0%100% | 69,277−28.1%100% | 72,944−17.2%100% | 71,089−19.7%100% | 98,768+34.6%100% | 96,379+35.9%100% | 88,092+19.3%100% | 88,545—100% | 73,384—100% | 70,912—100% | 73,871—100% | |
| Accounts payable | 5,187—7.2% | 5,187—7.2% | 1,401—2.0% | — | 2,339—3.2% | — | — | — | — | — | — | — | — | |
| Debt due within a year | — | — | — | — | — | — | — | — | — | — | — | 3,000—4.2% | 580—0.8% | |
| Current liabilities | 16,282—22.5% | 16,282−6.2%22.5% | 12,494−16.0%18.1% | 13,701+3.2%19.8% | 18,627+21.8%25.5% | 17,358+21.0%24.4% | 14,876+28.6%15.1% | 13,281+4.2%13.8% | 15,290+11.1%17.4% | 14,340—16.2% | 11,566—15.8% | 12,746—18.0% | 13,768—18.6% | |
| Long-term debt | 46,723—64.7% | 46,723+3.6%64.7% | 46,477+5.1%67.2% | 46,226+6.5%66.7% | 45,971+49.8%63.0% | 45,090+49.9%63.4% | 44,217+208%44.8% | 43,402+395%45.0% | 30,689+237%34.8% | 30,077—34.0% | 14,371—19.6% | 8,768—12.4% | 9,113—12.3% | |
| Lease liabilities (non-current) | 1,565—2.2% | 1,565−20.3%2.2% | 1,670+58.8%2.4% | 1,771+62.8%2.6% | 1,869+51.1%2.6% | 1,963+39.5%2.8% | 1,051−30.5%1.1% | 1,088−33.1%1.1% | 1,237−28.8%1.4% | 1,407—1.6% | 1,513—2.1% | 1,626—2.3% | 1,737—2.4% | |
| Non-current liabilities | 48,288—66.8% | 48,288+1.5%66.8% | 48,718+0.4%70.5% | 48,557+4.6%70.1% | 48,388+42.8%66.3% | 47,590+36.9%66.9% | 48,500+138%49.1% | 46,430+206%48.2% | 33,890+118%38.5% | 34,751—39.2% | 20,416—27.8% | 15,154—21.4% | 15,515—21.0% | |
| Total liabilities | 64,570—89.4% | 64,570−0.6%89.4% | 61,212−3.4%88.5% | 62,258+4.3%89.9% | 67,014+36.3%91.9% | 64,948+32.3%91.4% | 63,376+98.2%64.2% | 59,711+114%62.0% | 49,180+67.9%55.8% | 49,091—55.4% | 31,982—43.6% | 27,900—39.3% | 29,283—39.6% | |
| Retained earnings | −76,312—−106% | −76,312—−106% | −74,892—−108% | −74,503—−108% | −75,303—−103% | −73,694—−104% | −43,288—−43.8% | −41,312—−42.9% | −37,784—−42.9% | −36,246—−40.9% | −33,388—−45.5% | −29,898—−42.2% | −28,037—−38.0% | |
| Shareholders' equity | 7,666—10.6% | 7,666+24.7%10.6% | 7,943−77.6%11.5% | 7,029−80.8%10.1% | 5,938−84.9%8.1% | 6,149−84.5%8.6% | 35,399−15.1%35.8% | 36,671−15.3%38.0% | 39,404−12.1%44.7% | 39,784—44.9% | 41,706—56.8% | 43,291—61.0% | 44,832—60.7% | |
| Minority interests | — | — | −9.0—−0.0% | −9.0—−0.0% | −8.7—−0.0% | −8.4—−0.0% | −7.5—−0.0% | −3.4—−0.0% | −492—−0.6% | −330—−0.4% | −304—−0.4% | −279—−0.4% | −244—−0.3% | |
| Total equity | 7,666—10.6% | 7,666+24.8%10.6% | 7,934−77.6%11.5% | 7,019−80.9%10.1% | 5,930−84.8%8.1% | 6,141−84.4%8.6% | 35,392−14.5%35.8% | 36,668−14.7%38.0% | 38,912−12.7%44.2% | 39,454—44.6% | 41,402—56.4% | 43,012—60.7% | 44,588—60.4% | |
| Total liabilities and equity | 72,235—100% | 72,235+1.6%100% | 69,146−30.0%100% | 69,277−28.1%100% | 72,944−17.2%100% | 71,089−19.7%100% | 98,768+34.6%100% | 96,379+35.9%100% | 88,092+19.3%100% | 88,545—100% | 73,384—100% | 70,912—100% | 73,871—100% | |
| Shares outstanding | 9.2—— | 9.2+2.8%— | 9.2+3.3%— | 9.2+2.9%— | 8.9+2.2%— | 8.9+2.1%— | 8.9+1.8%— | 8.9+3.3%— | 8.8+2.6%— | 8.7—— | 8.7—— | 8.6—— | 8.5—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 2,488−38.3%2.2% | 613+0.4%2.2% | 619−10.1%2.2% | 587−47.8%2.1% | 668*−58.4%2.4% | 611−12.3%2.3% | 689r1,114−37.7%2.7% | 1,124+1.7%4.8% | 1,608*+46.9%6.1% | 697r1,104—3.2% | 1,106—5.5% | 1,105—6.0% | 1,095*—6.2% | |
| Share-based compensation | 4,977−3.7%4.4% | 1,271*+3.1%4.5% | 1,496*+4.2%5.3% | 1,028−21.2%3.7% | 1,182*−1.1%4.3% | 1,232+20.2%4.7% | 1,435+1.7%5.6% | 1,305+62.4%5.6% | 1,196*+38.9%4.5% | 1,025—4.7% | 1,412r1,083—7.0% | 803—4.3% | 861*—4.9% | |
| Cash from operating activities | 7,423+96.7%6.6% | 3,904*+79.4%13.7% | 2,038*−23.5%7.2% | −2,465—−8.9% | 3,945*+323%14.3% | 2,176*+6.1%8.3% | 2,664*—10.3% | −1,999—−8.5% | 932*—3.5% | 2,050*—9.5% | −1,412*—−7.0% | −1,594—−8.6% | −849*—−4.8% | |
| Capital expenditure | −131—−0.1% | 0*—0.0% | −5.3*—−0.0% | −44—−0.2% | −82*—−0.3% | −1,059*—−4.0% | −1,761*—−6.8% | −1,723—−7.4% | −72*—−0.3% | −9.1*—−0.0% | −59*—−0.3% | −66—−0.4% | −54*—−0.3% | |
| Intangible assets bought | — | — | — | — | 0*—0.0% | 0*—0.0% | — | — | — | — | — | — | — | |
| Acquisitions, net of cash acquired | — | — | — | — | — | — | — | — | — | — | — | — | 0*—0.0% | |
| Cash from investing activities | −4,253—−3.8% | −1,758*—−6.2% | −5.3*—−0.0% | −44—−0.2% | −2,445*—−8.9% | −3,421*—−13.0% | −3,928*—−15.2% | −5,180—−22.1% | −130*—−0.5% | −6,357*—−29.3% | −59*—−0.3% | −66—−0.4% | −54*—−0.3% | |
| Cash from financing activities | −1,322−118%−1.2% | −780*—−2.7% | −206*—−0.7% | −475−104%−1.7% | 139*—0.5% | −775*−105%−2.9% | −2,465*−151%−9.6% | 11,988—51.2% | −1,201*—−4.6% | 14,433*—66.6% | 4,793*—23.8% | −659—−3.6% | −186*—−1.1% | |
| Change in cash | 1,848—1.7% | 1,367*—4.8% | 1,827*—6.5% | −2,984−162%−10.7% | 1,639*—6.0% | −2,019*−120%−7.7% | −3,729*−212%−14.5% | 4,810—20.5% | −399*—−1.5% | 10,127*—46.7% | 3,322*—16.5% | −2,319—−12.5% | −1,089*—−6.2% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What Sanara MedTech Inc. sells: revenue by product line, fiscal 2025#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.
Products and services
- Soft Tissue Repair Products$91 M89%+20%
- Bone Fusion Products$12 M11%+12%
Source: SEC annual report (XBRL data) · as of Dec 31, 2025
Executive pay at Sanara MedTech Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Seth D. Yon | $2.3 M | $1.5 M | $740 K | $51 |
| 2024Seth D. Yon | $1.7 M | $1.2 M | $524 K | $112 |
| 2023Zachary B. Fleming | $910 K | $784 K | $708 K | $82 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at Sanara MedTech Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Acquisition or sale completed 1 · Directors and officers 3 · Material agreement 4 · Agreement ended 1 · Shareholder vote 3 · Results announced 12
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Material agreement | 8-K/A | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Shareholder vote | 8-K | |
| Agreement ended | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Acquisition or sale completedMaterial agreement | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026
Acquisitions and funding#
1 acquisitions, $3 M paid where reported
Businesses it acquired
| Acquired | Acquisition date | Completion | Price | Stake | Source |
|---|---|---|---|---|---|
| Care PICS | 2025 | — | $3 M | — | Annual report |
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Aug 2023 | $3 M | Private placement after listing | $2 to $10 million | 1 | equity | SEC |
| Jul 2022 | $16 M | Private placement after listing | $10 to $50 million | 1 | equity | SEC |
| Apr 2022 | $15 M | Private placement after listing | $10 to $50 million | 46 | equity | SEC |
| Jan 2021 | $1 M | Private placement after listing | Under $2 million | 2 | equity | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
H-1B hiring at Sanara MedTech Inc.#
1 labor condition applications certified in fiscal 2025 for 1 positions, at a median wage of $84 K a year.
| Job title | Positions | Median wage offered |
|---|---|---|
| Biomedical EngineerBioengineers and Biomedical Engineers | 1 | $84 K |
Where: San Antonio, TX 1
| Fiscal year | Certified | Positions | Median wage | Filed |
|---|---|---|---|---|
| FY2025 | 1 | 1 | $84 K | 1 |
| FY2024 | 1 | 1 | $200 K | 1 |
Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Sanara MedTech Inc
How Sanara MedTech Inc. compares in Medical Care Facilities
- Market cap$304 M · higher than 21% of 113
- Revenue$103 M · higher than 14% of 131
- Net margin-2.7% · higher than 12% of 127
- Revenue growth19.0% · higher than 87% of 53
- Price / sales2.7× · lower than 33% of 82
- Price / book51.2× · lower than 3% of 71
- FCF yield0.7% · higher than 28% of 33
Peer comparison · Medical Care Facilities
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Sanara MedTech Inc.🇺🇸 | $304 M | — | -2.7% | +19.0% |
| HCA Healthcare, Inc.🇺🇸 | $96.8 B | 14.3× | 8.6% | +7.1% |
| Fresenius SE & Co. KGaA🇩🇪 | $30.7 B | 20.4× | 5.5% | -3.4% |
| Dr. Sulaiman Al Habib Medical Services Group Company🇸🇦 | $22.2 B | 34.6× | 17.5% | +9.6% |
| Tenet Healthcare Corporation🇺🇸 | $21.4 B | 5.6× | 17.2% | +3.1% |
| IHH Healthcare Berhad🇲🇾 | $18.1 B | 34.8× | 8.2% | — |
| JD Health International Inc.🇨🇳 | $15.7 B | 20.2× | 7.3% | — |
| Apollo Hospitals Enterprise Limited🇮🇳 | $13.5 B | 64.2× | 7.8% | — |
| Fresenius Medical Care AG🇩🇪 | $12.4 B | 11.3× | 5.0% | +5.8% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
Sources and freshness
- Market cap:
- Oct 20, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Sanara MedTech Inc.? Verify and update this profile — free
Show Sanara MedTech Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.